Phase 1 Pharmacokinetic Study of MK-0646 (Dalotuzumab), an Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody, in Combination With Cetuximab and Irinotecan in Japanese Patients With Advanced Colorectal Cancer
Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-013-2240-8
Full Text
Open PDFAbstract
Available in full text
Date
August 7, 2013
Authors
Publisher
Springer Science and Business Media LLC